Publications by authors named "Nawel Belmecheri"
Purpose: We report the case of an adult patient diagnosed with Hodgkin's lymphoma who was scheduled for Pembrolizumab after failure of standard therapy. After three well-tolerated courses of Pembrolizumab, a PET scan showed a favorable outcome and a fourth course of Pembrolizumab was started. Unexpectedly, extremely severe toxicities (i.
View Article and Find Full Text PDFArticle Synopsis
- * 32 patients were treated with a combination of Rituximab and Lenalidomide (R2) over a median follow-up of 22.6 months, but the treatment only achieved a 12.5% response rate.
- * The results showed a median progression-free survival of 2.6 months and a median overall survival of 9.3 months, leading researchers to conclude that the R2 regimen is not advisable for high-risk patients in this group.
Peripheral T-cell lymphomas are characterized by a poor clinical outcome. We retrospectively analyzed 208 adults treated in our institution between 2000 and 2011. Median age at diagnosis was 55 years.
View Article and Find Full Text PDF